Olanzapine (Zyprexa Relprevv) vs Ziprasidone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Olanzapine (Zyprexa Relprevv)

Marketed by Cheplapharm Arzneimittel GmbH and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00088478 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 402 patients. All three tested doses of the long-acting olanzapine injection produced a significantly greater reduction in psychiatric symptom severity (PANSS) than placebo.

Reported efficacy

Demonstrate superiority of IM olanzapine depot 300 mg/2 weeks, 405 mg/4 weeks, and 210 mg/2 weeks dosages compared with placebo in the treatment of patients with schizophrenia: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each). (met)

Result source: NCT00088478

Ziprasidone

Marketed by Viatris and partners

Approved in Schizophreniasmall molecule
Partial signal

NCT00159770 · Phase 3 · completed

This 12-week, open-label, multicentre trial randomized 293 patients with chronic schizophrenia to ziprasidone (n=147) or to a comparator group of olanzapine, risperidone or quetiapine chosen by the investigator (n=146). The primary endpoint was total PANSS score, tested for non-inferiority with a margin of 7 points to the disadvantage of ziprasidone. Ziprasidone was non-inferior to the comparator group on total PANSS and on all subscores (P<0.0001), so the primary endpoint was met. The figures come from the peer-reviewed paper (Lublin et al., World J Biol Psychiatry 2009), whose abstract does not give a confidence interval.

Next expected readout: February 2027 · NCT03781115 (registry estimate)

Reported efficacy

Number of Events Recorded Based on Ziprasidone Side Effects Checklist During Randomized Trial (From Baseline up to Week 8); Change From Baseline in Simpson Angus Scale for Extrapyramidal Symptoms (SAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in the Barnes Akathisia Scale (BAS) (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Participants With High and Low Levels in Serum Prolactin Concentration (Baseline, Week 8); Vital Signs: Systolic and Diastolic Blood Pressure Levels (Baseline, Week 1, Week 2, Week 4, Week 6, Week 8); Electrocardiogram (EKG): Number of Participants With an Increase From Baseline to Corrected QT (QTc) Interval >/= 500 Milliseconds (Msec) (6 hours after dosing of Weeks 1, 2 and 8); Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline, Week 2, Week 4, Week 6, Week 8); Percentage of Participants With Response (Baseline, Week 2, Week 4, Week 6, Week 8); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score (Baseline, Week 2, Week 4, Week 6, Week 8); Number of Treatment-emergent Adverse Events During Randomized Trial (From Baseline up to Week 8): Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). (missed)

Result source: NCT00403546

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOlanzapine (Zyprexa Relprevv)Ziprasidone
PANSS total, change—Not posted · NCT00088491—Not posted · NCT00159770
CGI-S, change-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606
PANSS response—Not posted · NCT00088491—Not posted · NCT00159770
PSP, change—Not posted · NCT00088491—Not posted · NCT00159770
Relapse (% of patients)20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489—Not posted · NCT00159770

PANSS total, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Ziprasidone
—Not posted · NCT00159770

CGI-S, change

Olanzapine (Zyprexa Relprevv)
-0.4 vs -0.3vs Oral Olanzapinewk 104 · n 121NCT00320489
Ziprasidone
-1.2 vs -1.2vs Haloperidolwk 0.43 · n 188NCT00723606

PANSS response

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Ziprasidone
—Not posted · NCT00159770

PSP, change

Olanzapine (Zyprexa Relprevv)
—Not posted · NCT00088491
Ziprasidone
—Not posted · NCT00159770

Relapse (% of patients)

Olanzapine (Zyprexa Relprevv)
20.1% vs 18.5%vs Oral Olanzapinen 264NCT00320489
Ziprasidone
—Not posted · NCT00159770
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Olanzapine (Zyprexa Relprevv): 7 of 7 rows · Ziprasidone: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlanzapine (Zyprexa Relprevv)
Rows use multiple source trials
Ziprasidone
Rows use multiple source trials
BPRS Total
absolute change · score
-0.96 vs -0.91 Oral Olanzapine score @ 104wka,b,c
NCT00320489 · Phase 3 · monotherapy
-17.32 vs -18.44 Haloperidol score @ 0.43wka,b,c
NCT00723606 · Phase 3 · registry result, not featured evidence
CGI-S
absolute change · score
No placebo or comparator arm
-0.17 score @ 313wkd,a,b,e
NCT00088465 · Phase 3 · registry result, not featured evidence
-0.76 score @ 16wkd,a,b,e
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
0.3 score @ 330wka,b,f
NCT00088465 · Phase 3 · registry result, not featured evidence
-8.62 score @ 8wkHigh dosea,b,f
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
Dropout rate
54.9%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
60.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
26.8%
NCT00338949 · Phase 4 · registry result, not featured evidence
58.5%
NCT00406315 · Phase 4 · registry result, not featured evidence
12.5%
NCT00351000 · Phase 4 · registry result, not featured evidence
2.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
99.1%
NCT00139737 · Phase 3 · registry result, not featured evidence
88.4%
NCT00174447 · Phase 3 · registry result, not featured evidence
35.7%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Discontinued due to AEs
9.8%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
8.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
—High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
—
NCT00338949 · Phase 4 · registry result, not featured evidence
16.2%
NCT00406315 · Phase 4 · registry result, not featured evidence
—
NCT00351000 · Phase 4 · registry result, not featured evidence
1.1%
NCT00723606 · Phase 3 · registry result, not featured evidence
16.9%
NCT00139737 · Phase 3 · registry result, not featured evidence
44.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
—
NCT00538642 · Phase na · registry result, not featured evidence
—
NCT00225498 · Phase na · registry result, not featured evidence
Serious AEs
9.5%g
NCT00320489 · Phase 3 · monotherapy
show 1 more result
18.3%
NCT00088465 · Phase 3 · registry result, not featured evidence
—High doseh
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 9 more results
10.5%High dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
6.7%
NCT00338949 · Phase 4 · registry result, not featured evidence
9.1%
NCT00406315 · Phase 4 · registry result, not featured evidence
0%
NCT00351000 · Phase 4 · registry result, not featured evidence
0%
NCT00723606 · Phase 3 · registry result, not featured evidence
9.7%
NCT00139737 · Phase 3 · registry result, not featured evidence
30.2%
NCT00174447 · Phase 3 · registry result, not featured evidence
0%
NCT00538642 · Phase na · registry result, not featured evidence
0%
NCT00225498 · Phase na · registry result, not featured evidence
Most frequent reported AEs
g
weight increased 16.7%
insomnia 11%
anxiety 9.8%
NCT00320489 · Phase 3 · monotherapy
show 1 more result
weight increased 14.4%
anxiety 9.7%
insomnia 9.7%
NCT00088465 · Phase 3 · registry result, not featured evidence
High doseh
hypertension 18.4%
somnolence 15.8%
headache 10.5%
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 6 more results
insomnia 6.7%
akathisia 3.3%
NCT00338949 · Phase 4 · registry result, not featured evidence
insomnia 19.1%
somnolence 14.5%
nausea 11.6%
NCT00406315 · Phase 4 · registry result, not featured evidence
difficulty breathing 4.2%
dizziness 4.2%
NCT00351000 · Phase 4 · registry result, not featured evidence
dizziness 3.7%
somnolence 3.7%
akathisia 3.2%
NCT00723606 · Phase 3 · registry result, not featured evidence
electrocardiogram qt prolonged 13.9%
insomnia 6.3%
anxiety 4.5%
NCT00139737 · Phase 3 · registry result, not featured evidence
anxiety 23.3%
insomnia 16.3%
schizophrenia 14%
NCT00174447 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 0.43 weeks versus 104 weeks.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. eAssessment timepoints differ: 16 weeks versus 313 weeks.
  6. fAssessment timepoints differ: 8 weeks versus 330 weeks.
  7. gPopulation comparability has not been reviewed for these studies.
  8. hPopulation comparability has not been reviewed for 8 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olanzapine (Zyprexa Relprevv)

Time to Discontinuation Any Reason Median 21.17 vs 22.26 Oral Olanzapine months
time to event · months
NCT00320489 · Phase 3 · monotherapy · converted to months from 644.5 days as posted
QLS Total 8.15 vs 7.24 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Component Summary 0.43 vs 0.84 Oral Olanzapine score @ 104wk
absolute change · score
Physical Score Detail Change Week 104 (n=124,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Physical Functioning 1.35 vs 2.44 Oral Olanzapine score @ 104wk
absolute change · score
Physical Functioning Change Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Physical 10.7 vs 13.76 Oral Olanzapine score @ 104wk
absolute change · score
Role-Physical Change at Week 104 (n=130,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Bodily Pain 3.23 vs -0.6 Oral Olanzapine score @ 104wk
absolute change · score
Bodily Pain Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 General Health 2.69 vs 5.32 Oral Olanzapine score @ 104wk
absolute change · score
General Health Change at Week 104 (n=128,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Social Functioning 8.13 vs 5.1 Oral Olanzapine score @ 104wk
absolute change · score
Social Functioning Change at Week 104 (n=131,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 Vitality 7.95 vs 9.01 Oral Olanzapine score @ 104wk
absolute change · score
Vitality Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
SF-36 - Role Emotional 16.38 vs 17.59 Oral Olanzapine score @ 104wk
absolute change · score
Role-Emotional Change at Week 104 (n=129,134)
NCT00320489 · Phase 3 · monotherapy
EQ-5D 0.07 vs 0.09 Oral Olanzapine score @ 104wk
absolute change · score
NCT00320489 · Phase 3 · monotherapy
SUMD Total -0.72 vs -0.5 Oral Olanzapine score @ 104wk
absolute change · score
Total Score (Items 1-5) Change to Week 104
NCT00320489 · Phase 3 · monotherapy

+ 11 further endpoints in the CSV export.

Ziprasidone

PANSS 24.2% (n=33) @ 2wkHigh dose
responder rate · % of participants
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 3 more results
23.1% (n=33) @ 4wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
36.4% (n=33) @ 6wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
33.3% (n=33) @ 8wkHigh dose
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
CGI-I -0.57 score @ 8wkHigh dose
absolute value · score
No placebo or comparator arm
NCT00403546 · Phase 3 · combination · Schizophrenia · phase 3
show 1 more result
2.7 score @ 16wk
NCT00406315 · Phase 4 · registry result, not featured evidence
Insulin Sensitivity 0.407 vs 0.072 Control minutes @ 26wk
absolute change · minutes
NCT00338949 · Phase 4 · registry result, not featured evidence
Visceral Adipose Tissue Volume 392 vs 315 Control mm @ 26wk
absolute change · mm
NCT00338949 · Phase 4 · registry result, not featured evidence
Weight -1.09 kg @ 16wk
absolute change · kg
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
Total Cholesterol Change mg/dL -3 mg @ 16wk
absolute change · mg
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
HbA1c 0.1% (n=127) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
Fasting Glucose Change mg/dL 0.17 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 3 mg/dL as posted
show 2 more results
0.28 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 5 mg/dL as posted
-0.25 mmol/L @ 6wk*
NCT00351000 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -4.5 mg/dL as posted
Fasting Insulin 134.8 mL @ 16wk
absolute change · mL
No placebo or comparator arm
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Total -6.61 score @ 16wk
absolute change · score
No placebo or comparator arm
Total Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Positive Subscale -2.43 score @ 16wk
absolute change · score
No placebo or comparator arm
Positive Subscale Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence
PANSS Negative Subscale -0.92 score @ 16wk
absolute change · score
No placebo or comparator arm
Negative Subscale Score, Week 16 LOCF (n=231)
NCT00406315 · Phase 4 · registry result, not featured evidence

+ 17 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olanzapine (Zyprexa Relprevv)'s landscape · Ziprasidone's landscape